Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with IL-2/IFN-alpha in mRCC
NCT01274273Phase 2Unknown
- Sponsor
- Aarhus University
- Start
- Oct 2009
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in metastatic renal cell carcinoma (mRCC), sponsored by Aarhus University. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01274273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01274273.